BIO26: Engineering Anti-platelet polymers for regenerative cardiovascular applications

Thrombogenesis is the main failure cause of implantable cardiovascular devices. Thrombus formation not only occludes devices but exacerbates immune responses responsible for foreign body reaction. Biodegradable polymers modified with anticoagulating moieties represent a strategy to overcome these limitations. Herein, we propose the use of a novel polyester urethane urea (PEUU) with pendant carboxyl groups for functionalization with different anti-platelet deposition molecules. PEUU was synthesized from PCL (Polycaprolactone), 1,4-diisocyanatobutane and putrescine, and then chemically oxidized to introduce carboxyl groups in the polymer backbone (PEUU-COOH). PEUU-COOH was functionalized in-situ with Polyethyleneimine mW 400 (PEI), 4 arm Polyethylene Glycol (PEG-4-Arm-NH2), seleno-L-cystine, heparin sodium and fondaporinux as anti-platelet deposition molecules. After solvent casting, functionalization was confirmed via Fourier-transformed infrared spectroscopy (FTIR) and X-ray photoelectron spectroscopy (XPS). Metabolic activity (MTT) and hemolysis assays were performed to validate biocompatibility. Anti-platelet activity of PRP exposed films was examined via a platelet aggregation assay, through an activation assay via lactate dehydrogenase (LDH), and by surface imaging with scanning electron microscopy (SEM). Whole-blood clotting time quantification assay was carried out to evaluate anticogulating properties. Upon oxidation, PEUU exhibited COOH pendant groups that were successfully employed to conjugate the anti-platelet molecules, obtaining homogeneous films. Overall cytotoxicity was below 20% and the hemolysis was below 5%, suggesting high biocompatibility and hemocompatibility. The most potent anticoagulant activity was obtained for heparin-functionalized materials followed by PEG-4-Arm-NH2 and PEI. Surprisingly, Seleno-L-cystine and Fondaporinux showed no anti-platelet activity. Results indicate that the polymers introduced here are a promising strategy to avoid thrombogenesis in vascular grafts.